Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy

TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults

(2022) Guilherme Harada et al.   Cancer Genetics

Dramatic response of STRN-NTRK-fused malignant glioneuronal tumor to larotrectinib in adult

(2021) Julie Boyer et al.   NEURO-ONCOLOGY

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population

(2021) C. B. Westphalen et al.   npj Precision Oncology

NTRK-rearranged mesenchymal tumours: diagnostic challenges, morphological patterns and proposed testing algorithm

(2020) Daniel D. Wong et al.   PATHOLOGY

Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from TRK Inhibitor Therapy

(2019) Susan J. Hsiao et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms

(2019) James P. Solomon et al.   CANCER RESEARCH

NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls

(2019) James P. Solomon et al.   MODERN PATHOLOGY

Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer

(2019) A Amatu et al.   ANNALS OF ONCOLOGY

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

(2018) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular characterization of cancers with NTRK gene fusions

(2018) Zoran Gatalica et al.   MODERN PATHOLOGY

NTRK fusion-positive cancers and TRK inhibitor therapy

(2018) Emiliano Cocco et al.   Nature Reviews Clinical Oncology

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101

(2015) R. C. Doebele et al.   Cancer Discovery